National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 7 of 41
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
NCT04193189
Evaluation of AMG 714 for Vitiligo
NCT04338581
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
NCT04640168
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
NCT04588363
Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
NCT04408950
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
NCT04212091
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
NCT03891901
ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19
NCT04583969
ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
NCT04583956
Phase 1 Study of SAR440894 vs Placebo
NCT04441905
Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults
NCT04579250
Safety and Pharmacokinetics of VT-1598
NCT04208321
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
NCT03760458
SARS-COV2 Pandemic Serosurvey and Blood Sampling
NCT04334954
ACTIV-2: A Study for Outpatients With COVID-19
NCT04518410
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
NCT04492475
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780268
ACTIV-3: Therapeutics for Inpatients With COVID-19
NCT04501978
Surveillance of Individuals Following SARS-CoV-2 Infection
NCT04383444
Collection of Anti-SARS-CoV-2 Immune Plasma
NCT04344977
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
NCT04401436
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
NCT04358068
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
NCT04401579
COVID-19: Human Epidemiology and Response to SARS-CoV-2
NCT04375761
Immunophenotyping Assessment in a COVID-19 Cohort
NCT04378777
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
NCT04283461
Adaptive COVID-19 Treatment Trial (ACTT)
NCT04280705
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males
NCT04692077
Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
NCT04177355
Trial to Evaluate CIS43LS in Healthy Adults
NCT04206332
Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
NCT03739996
Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally
NCT04047420
Treg Modulation With CD28 and IL-6 Receptor Antagonists
NCT04066114
Safety and Pharmacokinetics of Rezafungin
NCT04117607
H1N1v Virus Challenge Study in Healthy Subjects
NCT04044352
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
NCT04025580
Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
NCT04019444
Suppression Of Bacterial Vaginosis (BV) [SUBVert]
NCT03930745
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
NCT03934541
Asymptomatic Congenital CMV Treatment
NCT03301415
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
NCT03787095
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
NCT03881696
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants
NCT03928821
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
NCT03978091
Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine
NCT04009824
Intravenous Fosfomycin Pharmacokinetics Study
NCT03910673
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
NCT03916185
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
NCT03770273
Flublok or Fluzone With Advax-CpG55.2 or AF03
NCT03945825
A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells
NCT03856996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.